Streetbeat News

Stock Prices

LLY

Eli Lilly (NYSE:LLY) has significantly outperformed the market over the past 5 years, with an annualized return of 43.4%, turning a $1000 investment into $6,046.37. The company's market capitalization stands at $703.02 billion.

Portfolio Pulse from Benzinga Insights

February 13, 2024 | 5:00 pm

BIIB

Eight analysts have recently shared their views on Biogen (NASDAQ:BIIB), with opinions ranging from bullish to bearish. The average 12-month price target for BIIB has been adjusted to $291.0, down from $302.00, reflecting a 3.64% decline. Analyst actions include maintaining, raising, and lowering ratings and price targets, indicating varied perceptions of Biogen's market position. Biogen's financial performance shows strong net margin and ROE, but its revenue growth and market capitalization are below industry averages.

Portfolio Pulse from Benzinga Insights

February 13, 2024 | 5:00 pm

BRX

Stifel has maintained its Hold rating for Brixmor Property Group (NYSE:BRX) and increased its price target from $22.75 to $24.00. Despite a recent 3.02% drop in share price to $21.87, the new target suggests a potential 9.74% increase. Brixmor, a US-based REIT, operates grocery-anchored shopping centers.

Portfolio Pulse from Benzinga Insights

February 13, 2024 | 5:00 pm

Goldman Sachs has reaffirmed its Buy rating on Bunge Global (NYSE:BG) but reduced its price target from $141.00 to $126.00. Despite this reduction, the new target suggests a potential upside of 38.46% from the current price of $91.00. Bunge Global, a leading agribusiness and food company, operates across the farm-to-consumer food chain, with its primary revenue coming from the Agribusiness segment.

Portfolio Pulse from Benzinga Insights

February 13, 2024 | 5:00 pm

WST

Keybanc has maintained its Overweight rating for West Pharmaceutical Servs (NYSE:WST) and increased its price target from $440.00 to $470.00. Despite a slight decrease in share price over the last 24 hours, the new price target suggests a potential 16.14% increase. West Pharmaceutical Services is a key supplier in the pharmaceutical and biotech industries, with a significant portion of its revenue generated internationally.

Portfolio Pulse from Benzinga Insights

February 13, 2024 | 5:00 pm

DTE

Barclays has maintained its Overweight rating for DTE Energy (NYSE:DTE) but lowered its price target from $113.00 to $112.00. DTE Energy's shares have fallen by 1.19% in the last 24 hours to $105.11. The new price target suggests a potential upside of 6.56%. DTE Energy operates primarily in Michigan, with the majority of its earnings coming from its regulated utilities, DTE Electric and DTE Gas, alongside nonutility businesses.

Portfolio Pulse from Benzinga Insights

February 13, 2024 | 5:00 pm

MHK

Truist Securities has reaffirmed its Buy rating on Mohawk Industries (NYSE:MHK), increasing its price target from $98.00 to $127.00. Mohawk Industries, a manufacturer of a broad range of flooring products, has seen its shares remain stable over the last 24 hours at $117.24. The new price target suggests a potential upside of 8.32% from the current share price. Mohawk Industries primarily generates its revenue from the United States, with the Global Ceramic segment being its most significant revenue contributor.

Portfolio Pulse from Benzinga Insights

February 13, 2024 | 5:00 pm

AEM

AGI

CDE

CGAU

EGO

FCX

GFI

GOLD

HMY

NEM

PAAS

SAND

WPM

Precious metals stocks are trading lower due to a rise in the US dollar, which was influenced by a higher-than-expected increase in January inflation.

Portfolio Pulse from Benzinga Newsdesk

February 13, 2024 | 4:57 pm

MAR

Marriott International (NASDAQ:MAR) reported Q4 adjusted earnings per share of $3.57, surpassing analyst expectations of $2.12, but missed revenue forecasts with $6.095 billion against a consensus of $6.20 billion. The company saw a worldwide RevPAR increase of 7.2% and added nearly 81,300 rooms globally in 2023. Despite these achievements, MAR shares fell by 5.60% to $234.90, likely due to the revenue miss and a cautious outlook for FY24, projecting adjusted EPS below analyst estimates.

Portfolio Pulse from Nabaparna Bhattacharya

February 13, 2024 | 4:55 pm

WK Kellogg shares are trading higher following the announcement of better-than-expected Q4 revenue results and the issuance of FY24 guidance.

Portfolio Pulse from Benzinga Newsdesk

February 13, 2024 | 4:54 pm